Evaxion Biotech is committed to the discovery and development of immunotherapies against cancer and infectious diseases
Since 2008, Evaxion has been redefining medicine, pioneering the discovery of neo-epitopes and antigens. We have constructed a robust product engine for the development of novel immunotherapies based on our two platforms, PIONEER and EDEN. Using state-of-the-art in silico tools, the platforms integrate biological data, artificial intelligence and supercomputing to rapidly predict, rank and optimize epitopes and antigens that elicit a highly protective immune response against cancer and infectious diseases.
Our office is situated in central Copenhagen and the heart of Medicon Valley, one of Europe’s largest international life-sciences cluster. With a primary focus on drug discovery and early drug development, we are building on a simple and scalable business model with manageable risk.